Geron (NASDAQ:GERN) Trading 4.7% Higher

Shares of Geron Co. (NASDAQ:GERN) traded up 4.7% during mid-day trading on Wednesday . The company traded as high as $3.78 and last traded at $3.75. 961,135 shares traded hands during trading, a decline of 91% from the average session volume of 11,179,831 shares. The stock had previously closed at $3.58.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. The Goldman Sachs Group boosted their price target on Geron from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Geron in a research report on Wednesday, April 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Geron in a research report on Thursday, April 11th.

Geron Stock Up 1.4 %

The firm has a 50 day moving average of $2.71 and a two-hundred day moving average of $2.23. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.16 and a current ratio of 3.16.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. During the same quarter last year, the company earned ($0.10) EPS. The company’s quarterly revenue was down 77.7% on a year-over-year basis. On average, equities research analysts forecast that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GERN. Vanguard Group Inc. boosted its position in shares of Geron by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 28,564,574 shares of the biopharmaceutical company’s stock worth $60,271,000 after purchasing an additional 1,914,328 shares during the last quarter. American International Group Inc. raised its holdings in Geron by 2.5% during the fourth quarter. American International Group Inc. now owns 254,663 shares of the biopharmaceutical company’s stock worth $537,000 after acquiring an additional 6,123 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Geron by 9.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 187,779 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 16,501 shares in the last quarter. GSA Capital Partners LLP raised its stake in Geron by 49.7% in the fourth quarter. GSA Capital Partners LLP now owns 170,420 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 56,591 shares during the period. Finally, Exome Asset Management LLC acquired a new position in shares of Geron in the fourth quarter valued at approximately $1,282,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.